Literature DB >> 10536203

The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat.

B Alessandri1, E Tsuchida, R M Bullock.   

Abstract

We tested the neuroprotective effect of a novel, high affinity serotonin (5-HT1A) agonist, BAY X3702, in a rat model of acute subdural hematoma (ASDH). Animals were treated with 0.01 mg/kg (n=8), 0.003 mg/kg (n=8) BAY X3702 or vehicle (n=4) 15 min before (i.v.) and after (continuous infusion) injection of 400 microl of autologous blood into the subdural space. The ischemic brain damage at 4 h after ASDH was 59.01+/-39 and 60.8+/-49 mm(3) for the low- and high-dose BAY X3702 group, respectively, which was significantly smaller compared to the vehicle-treated ASDH group (106.2+/-33 mm(3)). The result indicates that this novel, high affinity 5-HT(1A) agonist, BAY X3702, is neuroprotective in this model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10536203     DOI: 10.1016/s0006-8993(99)01948-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  13 in total

1.  Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.

Authors:  Adam S Olsen; Christopher N Sozda; Jeffrey P Cheng; Ann N Hoffman; Anthony E Kline
Journal:  J Neurotrauma       Date:  2012-04-23       Impact factor: 5.269

2.  The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window.

Authors:  Jeffrey P Cheng; Haris A Aslam; Ann N Hoffman; Ross D Zafonte; Anthony E Kline
Journal:  Neurosci Lett       Date:  2007-02-07       Impact factor: 3.046

Review 3.  Neuroprotection for ischemic stroke: two decades of success and failure.

Authors:  Yu Dennis Cheng; Lama Al-Khoury; Justin A Zivin
Journal:  NeuroRx       Date:  2004-01

Review 4.  5-HT1A receptor-regulated signal transduction pathways in brain.

Authors:  Abigail M Polter; Xiaohua Li
Journal:  Cell Signal       Date:  2010-04-02       Impact factor: 4.315

Review 5.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

6.  Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.

Authors:  Anthony E Kline; Amy K Wagner; Brian P Westergom; Rebecca R Malena; Ross D Zafonte; Adam S Olsen; Christopher N Sozda; Pallavi Luthra; Monisha Panda; Jeffery P Cheng; Haris A Aslam
Journal:  Behav Brain Res       Date:  2006-12-12       Impact factor: 3.332

Review 7.  5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Authors:  Jeffrey P Cheng; Jacob B Leary; Aerin Sembhi; Clarice M Edwards; Corina O Bondi; Anthony E Kline
Journal:  Brain Res       Date:  2015-11-21       Impact factor: 3.252

8.  A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning.

Authors:  Jeffrey P Cheng; Ann N Hoffman; Ross D Zafonte; Anthony E Kline
Journal:  Behav Brain Res       Date:  2008-07-01       Impact factor: 3.332

9.  Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT(1A) agonist in rat models of ischaemic stroke.

Authors:  Maria Ashioti; John S Beech; Andrew S Lowe; Michel Bernanos; Andrew McCreary; Michel M Modo; Steve C R Williams
Journal:  BMC Neurosci       Date:  2009-07-16       Impact factor: 3.288

10.  CEP biomarkers as potential tools for monitoring therapeutics.

Authors:  Kutralanathan Renganathan; Jiayin Gu; Mary E Rayborn; John S Crabb; Robert G Salomon; Robert J Collier; Michael A Kapin; Carmelo Romano; Joe G Hollyfield; John W Crabb
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.